3
Announcements
Trials
Browse
Landscape
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Thoracic Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parathyroid Neoplasms
1
Interventions
Carboplatin
5
Pemetrexed
4
pembrolizumab
3
osimertinib
3
entinostat
3
selpercatinib
2
durvalumab
2
camrelizumab
2
Erlotinib Hydrochloride
2
sotorasib
1
repotrectinib
1
pralsetinib
1
patritumab
1
napabucasin
1
exemestane
1
cobimetinib
1
ceralasertib
1
capmatinib
1
alectinib
1
aflutinib
1
Toll-Like Receptor 1
1
TNFSF10 protein, human
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Injections
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Bronchial Neoplasms
×
Patient Reported Outcome Measures
×
Clear all
NCT03053297
2018-02-08
PANORAMA
AstraZeneca
Terminated
89 enrolled